The targeted therapy Avastin, in a combination or isolation, has the capability of considerably increasing response rates, survival rates, and progression-free survival times in patients suffering from recurrent glioblastoma, a deadly form of brain cancer.

Dr. Timothy Cloughesy, director of the Neuro-Oncology Program at UCLA’s Jonsson Comprehensive Cancer Center and senior author of the study, remarked that Avastin alone and Avastin given with CPT-11 can improve the response rate and overall survival to a considerable extent.

From News-Medical.Net:

The two-armed study enrolled 167 patients with recurrent glioblastoma. One arm evaluated Avastin used as a single agent, the other Avastin given with CPT-11. An independent radiological facility was used to measure tumor responses, Cloughesy said.

In the Avastin only arm, 28.2 percent of patients responded to the treatment, meaning their tumors shrunk by 50 percent or more, a significant increase from the historic 5 percent response rates. Of the 80 patients, 42.6 percent surpassed the six month mark without their disease progressing, up from the historic 15 to 20 percent of patients. Survival was 9.2 months, a slight increase of the typical six to seven month survival time.

In the arm studying Avastin with CPT-11, 37.8 percent of patients responded to the treatment, while 50.3 percent surpassed the six month progression-free survival mark. Overall survival was 8.7 months, a little less than the Avastin only study.

Cloughesy remarked that the findings of this study constitute a huge breakthrough as Avastin has proved itself to be of great usefulness for treating patients with recurrent glioblastoma. It was also remarked that Avastin brings the level of brain swelling down and can even help in reducing the doses of steroids to ensure marked improvement in function.

Bookmark It

Hide Sites

Tags: Avastin, brain cancer, recurrent glioblastoma, steroids

Posted in Steroid Cycles, Steroids and Anabolic Steroids, buy steroids, steroid nation